Dublin, March 19, 2025 (GLOBE NEWSWIRE) -- The "2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA" report has been added to ResearchAndMarkets.com's offering.
This report provides a compilation and analysis of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2024. In addition, publicly available 2024 sales data of biosimilar antibodies and proteins as well as of new biologic modalities such as gene and cell therapy and RNA (antisense, siRNA) are included in the report.
Individual product sales data are presented within the following groups:
- Cancer Antibodies
- Non-TNF Anti-Inflammatory mAbs
- Cardiometabolic Antibodies
- Anti-TNF Antibodies
- Ophthalmic Antibodies
- Insulin & Insulin Analogs
- Coagulation Factors
- Enzyme Replacement Therapy
- Neuromodulators (botulinumtoxins)
- Established Therapeutic Proteins
- Anti-Infective Antibodies
- Migraine Antibodies
- Other Proteins
- Biosimilar Antibodies & Proteins
- Gene, Cell & RNA Therapy
In the analytical part of the report, sales data from 2012 to 2024 are summarized for the class of products and their growth rates reported. The percentage of antibody sales of total biologics sales was calculated. The time course of sales of established therapeutic proteins (erythropoietins, interferon, G-CSF, hGH and FSH) are presented for the period of 2012-2024.
Sales and growth rates of cancer antibodies were analyzed by subgroup:
- Anti-PD-1 & PD-L1 Antibodies (Abs)
- Other Immuno-Oncology (I-O) Abs
- Anti-Her2 Abs
- Anti-EGFR Abs
- Anti-VEGF/-R Abs
- Anti-CD20 Abs
- Other Cancer Abs
In addition, 2024 sales data of target-specific cancer antibodies were calculated for PD-1; PD-L1; PD-1 x LAG3 FDC; PD-1 x CTLA4; PD-1 x VEGF; CD38; CTLA4; CD19 (x CD3); CCR4; Cell-Surface Glycoprotein CS1; RANKL; Nectin-4; CD30; TROP-2; CD79b; BCMA (x CD3); Folate Receptor 1; gp100 (x CD3); Ganglioside GD2; Interleukin-6; Tissue Factor; DLL3; CLDN18.2; IL-2R?/? (IL-15 superagonist).
Sales and growth rates of non-TNF anti-inflammatory antibodies were analyzed by therapeutic area:
- Dermatology
- Rheumatoid & Autoimmune
- Neuro-Inflammation
- Pulmonary & Respiratory
- Gastrointestinal
In addition, 2024 sales data of target-specific non-TNF anti-inflammatory antibodies were calculated for Interleukin-4 Receptor (IL-4R); p40 of IL-12/2;, p19 of IL-23; IL-17(R); IL-13; IL-31; Complement C5; B7-1 & B7-2 (CD80 & CD86); IL-6 Receptor; IL-1; BLyS +/- APRIL; Interferon alpha Receptor; Interferon gamma; Complement protein component 1 (C1s); CD20; FcRn; IL-5 (Receptor); IgE; TSLP and alpha(4)beta(7) integrin
Scope
- To highlight commercial success of novel antibody drug modalities, development of sales and growth rates of antibody-drug conjugates and of bispecific antibodies are shown for the years 2012/2015 to 2024.
- Company specific sales data for biosimilar antibodies and proteins are highlighted in a Table for the years 2020 to 2023 as far as published which allows a ranking of biosimilar companies based on total biosimilar revenues.
- Total sales for novel biologic drug modalities, i.e. gene and cell therapy and RNA-based biologics (antisense, siRNA, PMOs), are presented and were considered if published.
- Sales of innovator therapeutic antibodies and proteins were summarized per company and a ranking list was prepared for the TOP 30 companies regarding biologics sales in 2024.
- A total of 75 innovator therapeutic antibodies and proteins reached blockbuster status with 2024 sales exceeding US$ 1 billion, two drop outs were observed.
Key Topics Covered:
Biologics Sales per Class of Branded Originator Products
- Sales of Established Therapeutic Proteins 2012-2024
- Cancer Antibodies: Sales and Growth Rates by Subgroup 2013-2024
- Target-Specific Sales of Cancer Antibodies in 2024
- Non-TNF Anti-Inflammatory Antibodies: Sales and Growth Rates by Therapeutic Area 2013-2024
- Target-Specific Sales of Non-TNF Anti-Inflammatory Antibodies in 2024
- Antibody-Drug Conjugates: Sales by Product 2012-2024
- Antibody-Drug Conjugates: Growth Rates by Product 2012-2024
- Bispecific Antibodies and FDCs: Sales by Product 2015-2024
- Bispecific Antibodies and FDCs: Growth Rates by Product 2015-2024
- Biosimilar Antibodies & Proteins: Published Sales Data for 2024 by Company
- Other Biologics Based on DNA, RNA & Cells: Published Sales Data for 2024 by Product Category
Top 30 Company Ranking List for Sales of Innovator Biologics 2024
Blockbuster Biologics in 2024 (by generic name)
Individual Biologic Product Sales 2024
Cancer Antibodies
- PD-1 & PD-L1 Immuno-Oncology Antibodies
- Other Immuno-Oncology Antibodies
- . Cancer Antibodies
- Her2
- EGF-R
- CD20
- VEGF & VEGF-R
- Other Cancer Antibodies
Non-TNF Anti-Inflammatory Antibodies
- Dermatology
- Rheumatoid & Autoimmune
- Neuro-Inflammation (multiple sclerosis, myasthenia gravis)
- Pulmonary & Respiratory
- Gastrointestinal
Cardiometabolic Antibodies
Anti-TNF Antibodies
Ophthalmic Antibodies
Insulin and Insulin Analogs
Recombinant Coagulation Factors
Enzyme Replacement Therapy (ERT)
Neuromodulators (botulinumtoxins)
Established Therapeutic Proteins
- Erythropoiesis Stimulating Agent (ESA)
- human Growth Hormone (hGH)
- Interferon beta (IFN-?)
- Follicle Stimulating Hormone (FSH)
- Granulocyte Colony Stimulating Factor (G-CSF)
Migraine & Neurodegenerative Disease Antibodies
Anti-Infective Antibodies
Other Proteins
- Cardiometabolic Proteins
- Cancer Proteins
- Various Proteins
Selected Biosimilar Antibodies & Proteins
Selected Other Biologics
- RNA
- Cell Therapy
- DNA / Gene Therapy
For more information about this report visit https://www.researchandmarkets.com/r/ra7ci8
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
